After Credit Suisse and Barclays gave HCA Healthcare (NYSE: HCA) a Buy rating last month, the company received another Buy, this time from Oppenheimer. Analyst Michael Wiederhorn maintained a Buy rating on HCA Healthcare today and set a price target of $160.00. The company’s shares closed last Tuesday at $105.20.
According to TipRanks.com, Wiederhorn is a top 100 analyst with an average return of 15.4% and a 67.6% success rate. Wiederhorn covers the Healthcare sector, focusing on stocks such as Community Health, The Ensign Group, and Addus Homecare.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for HCA Healthcare with a $156.21 average price target, a 35.1% upside from current levels. In a report issued on April 6, Robert W. Baird also maintained a Buy rating on the stock with a $150.00 price target.
See today’s analyst top recommended stocks >>
HCA Healthcare’s market cap is currently $37.38B and has a P/E ratio of 11.50. The company has a Price to Book ratio of -13.94.
Based on the recent corporate insider activity of 90 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of HCA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
HCA Healthcare, Inc. is a health care services company, which engages in operating hospitals, freestanding surgery centers and emergency rooms, and urgent care centers. It offers a full range of services to accommodate such medical specialties as internal medicine, general surgery, cardiology, oncology, neurosurgery, orthopedics and obstetrics, as well as diagnostic and emergency services. The company was founded by Dr. Thomas Frist Sr., Dr. Thomas Frist Jr., and Jack Massey in 1968 and is headquartered in Nashville, TN.
